Cargando…

Combination Therapies Targeting Apoptosis in Paediatric AML: Understanding the Molecular Mechanisms of AML Treatments Using Phosphoproteomics

Paediatric acute myeloid leukaemia (AML) continues to present treatment challenges, as no “standard approach” exists to treat those young patients reliably and safely. Combination therapies could become a viable treatment option for treating young patients with AML, allowing multiple pathways to be...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ali, Ahlam A., Cairns, Lauren V., Clarke, Kathryn M., Blayney, Jaine K., Lappin, Katrina M., Mills, Ken I.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10058112/ https://www.ncbi.nlm.nih.gov/pubmed/36982791 http://dx.doi.org/10.3390/ijms24065717

Ejemplares similares

A compound combination screening approach with potential to identify new treatment options for paediatric acute myeloid leukaemia
por: Lappin, Katrina M., et al.
Publicado: (2020)

Multiplex Screening for Interacting Compounds in Paediatric Acute Myeloid Leukaemia
por: Cairns, Lauren V., et al.
Publicado: (2021)

Chronic loss of STAG2 leads to altered chromatin structure contributing to de-regulated transcription in AML
por: Smith, James S., et al.
Publicado: (2020)

Phosphoproteomic Characterization of Primary AML Samples and Relevance for Response Toward FLT3-inhibitors
por: Cucchi, David G. J., et al.
Publicado: (2021)

Proteomic and phosphoproteomic measurements enhance ability to predict ex vivo drug response in AML
por: Gosline, Sara J. C., et al.
Publicado: (2022)

RUNX1 mutation has no prognostic significance in paediatric AML: a retrospective study of the AML-BFM study group
por: Sendker, Stephanie, et al.
Publicado: (2023)

Phosphoproteomic Landscape of AML Cells Treated with the ATP-Competitive CK2 Inhibitor CX-4945
por: Rosales, Mauro, et al.
Publicado: (2021)

Significance of NPM1 Gene Mutations in AML
por: Hindley, Andrew, et al.
Publicado: (2021)

Rational Combinations of Targeted Agents in AML
por: Bose, Prithviraj, et al.
Publicado: (2015)

Phosphoproteomics of primary AML patient samples reveals rationale for AKT combination therapy and p53 context to overcome selinexor resistance
por: Emdal, Kristina B., et al.
Publicado: (2022)

Maintenance Therapy in AML
por: Reville, Patrick K., et al.
Publicado: (2021)

Towards a Better Understanding of Cohesin Mutations in AML
por: Cuartero, Sergi, et al.
Publicado: (2019)

The role of the proteasome in AML
por: Csizmar, C M, et al.
Publicado: (2016)

Targeting Apoptosis in AML: Where Do We Stand?
por: Krawiec, Kinga, et al.
Publicado: (2022)

AML1/ETO Oncoprotein Is Directed to AML1 Binding Regions and Co-Localizes with AML1 and HEB on Its Targets
por: Gardini, Alessandro, et al.
Publicado: (2008)

8-Hydroxydaidzein Induces Apoptosis and Inhibits AML-Associated Gene Expression in U-937 Cells: Potential Phytochemical for AML Treatment
por: Wu, Pei-Shan, et al.
Publicado: (2023)

CALCRL Gene is a Suitable Prognostic Factor in AML/ETO(+) AML Patients
por: Wang, Rongrong, et al.
Publicado: (2022)

MLN0128, a novel mTOR kinase inhibitor, disrupts survival signaling and triggers apoptosis in AML and AML stem/ progenitor cells
por: Zeng, Zhihong, et al.
Publicado: (2016)

Inhibition of autophagy enhances apoptosis induced by bortezomib in AML cells
por: Jiang, Lei, et al.
Publicado: (2021)

Genotype-outcome correlations in pediatric AML: the impact of a monosomal karyotype in trial AML-BFM 2004
por: Rasche, M, et al.
Publicado: (2017)

Phosphoproteome Analysis Reveals Differential Mode of Action of Sorafenib in Wildtype and Mutated FLT3 Acute Myeloid Leukemia (AML) Cells
por: Roolf, Catrin, et al.
Publicado: (2017)

The Challenge of AML in Older Patients
por: Burnett, Alan K
Publicado: (2013)

Targeting glutamine uptake in AML
por: Jacque, Nathalie, et al.
Publicado: (2014)

AML treatment in older adults
por: Sehgal, Alison, et al.
Publicado: (2015)

Impact of CNA on AML prognosis
por: Gonzales, Fanny, et al.
Publicado: (2017)

Treatments for children and adolescents with AML
por: Kim, Hyery
Publicado: (2020)

Emerging agents and regimens for AML
por: Liu, Hongtao
Publicado: (2021)

Von AML bis Zytokinfreisetzung
por: Klein, Friederike
Publicado: (2022)

Inherited predisposition to MDS/AML
por: Rio Machin, Ana, et al.
Publicado: (2018)

Switch of the mutation type of the NPM1 gene in acute myeloid leukemia (AML): relapse or secondary AML?
por: Webersinke, G, et al.
Publicado: (2014)

Analysis of AML genes in dysregulated molecular networks
por: Lee, Eunjung, et al.
Publicado: (2009)

Analysis of AML Genes in Dysregulated Molecular Networks
por: Lee, Eunjung, et al.
Publicado: (2009)

CEBPA-dependent HK3 and KLF5 expression in primary AML and during AML differentiation
por: Federzoni, Elena A., et al.
Publicado: (2014)

De novo AML exhibits greater microenvironment dysregulation compared to AML with myelodysplasia-related changes
por: Lopes, Matheus Rodrigues, et al.
Publicado: (2017)

Oncogenic Roles Of A Histone Methyltransferase SETDB2 In AML1-ETO Positive AML
por: Mu, Guangfu, et al.
Publicado: (2020)

IRF8 Is an AML-Specific Susceptibility Factor That Regulates Signaling Pathways and Proliferation of AML Cells
por: Liss, Franziska, et al.
Publicado: (2021)

Comparative analysis of extracellular vesicle isolation methods from human AML bone marrow cells and AML cell lines
por: Lang, Jonas B., et al.
Publicado: (2022)

Who Has Therapy-Related AML?
por: Gale, Robert Peter, et al.
Publicado: (2017)

Acute Myeloid Leukemia (AML) with Erythroid Predominance Exhibits Clinical and Molecular Characteristics that Differ from Other Types of AML
por: Zuo, Zhuang, et al.
Publicado: (2012)

PU.1 downregulation in murine radiation-induced acute myeloid leukaemia (AML): from molecular mechanism to human AML
por: Verbiest, Tom, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_b0v138392f38lg7dgum7927tk8